Drug Database
Back to search

Belgium· BE-AMP-SAM512791-00

Cimzia 200 mg

A certolizumab pegol product containing certolizumab pegol, registered in Belgium by UCB Pharma. The same ATC class is registered in 14 of our 19 countries.

ATC L04AB05

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedCimzia 200 mgATCL04AB05REGISTER NO.BE-AMP-SAM512791-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about certolizumab pegolAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Certolizumab pegol is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AB05 (certolizumab pegol), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search certolizumab pegol products by name

Certolizumab pegol · ATC L04AB05

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of certolizumab pegol costs, country by country.

Normalised to the WHO defined daily dose (14 mg), the median price runs from $0.17 in Finland to $41.63 in Switzerland — a ×241 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Certolizumab pegol · price per daily dose (14 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$41.63
  • FI Finland$0.17
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Certolizumab Pegol
Manufacturer
UCB Pharma
Country
Belgium (BE)
ATC code
L04AB05
ATC class
Certolizumab pegol
Defined daily dose
14 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    3730884
  • be_apb
    7724263

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

430 interactions on record for certolizumab pegol.

Graded by severity as the source publishes them — 286 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check certolizumab pegol against other medicinesHow interaction checks work

Certolizumab pegol · interactions on record

430 records

  • 286 severe
  • 137 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Certolizumab pegol in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All certolizumab pegol products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Cimzia
  • Liechtenstein · Cimzia
  • Norway · Cimzia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ad64495a-99bd-4970-9287-3b0e1c048fc3
GET /v1/drugs/ad64495a-99bd-4970-9287-3b0e1c048fc3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in dose-dispenser cartridge",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Cimzia 200 mg",
  "name_fr": "Cimzia 200 mg",
  "name_nl": "Cimzia 200 mg",
  "amp_code": "SAM512791-00",
  "strengths": [
    "200.0000"
  ],
  "pack_count": 4,
  "substances": [
    "Certolizumab Pegol",
    "Sodium Acetate",
    "Sodium Chloride"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Certolizumab Pegol",
  "authorisation_numbers": [
    "EU/1/09/544/009",
    "EU/1/09/544/008",
    "EU/1/09/544/010"
  ]
}
API referenceMCP serverPlans

See everything about certolizumab pegol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console